GliaPharm is a Swiss biotechnology company that develops treatments for neurological and psychiatric disorders.
GliaPharm est une entreprise suisse de biotechnologies active dans le développement de traitements de maladies neurologiques et psychiatriques.
GliaPharm receives support from Innosuisse for a project to develop specific cell therapy to treat neurological diseases in collaboration with Universities of Bern and Lausanne
GliaPharm receives grant for collaboration with HEPIA to setup a new 3D culture method using brain organoids from mouse and human-derived cells
GliaPharm presented at the European Congress of Neuropsychopharmacology - Symposium on "Beyond the Neurocentric Paradigm: Targeting Astrocytes and Neuroglial Interactions in CNS Disorders". September 13th 2020.